Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)

NCT05338099 | Completed Phase 1

• 1 other identifier: ENCell_2020_01
• Study Type: interventional
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Duchenne Muscular Dystrophy(DMD)

Conditions

Duchenne Muscular Dystrophy

Outcome Measures

Primary Outcomes (7)

• Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product

  Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

  Week 12 after treatment

• Determination of Dose-limiting toxicity (DLT) levels of EN001

  Among the adverse events occurring for 2 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE 5.0

  Up to Week 2 after dosing on Day 0

• Determination of Maximum tolerated dose (MTD) levels of EN001

  Among the adverse events occurring for 2 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE 5.0 Maximum tolerated dose defines the evaluated maximum dose level in which greater than two participants of six participants experience Dose-limiting toxicity (DLT) under the dose level. The dose level where two participants of six participants experience DLT will be the maximum tolerated dose.

  Up to Week 2 after dosing on Day 0

• Number of participants with Vital Signs abnormalities

  Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (℃) and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001. The number of participants with at least one potentially clinically significant abnormal vital sign finding were reported as treatment emergent adverse events (TEAEs).

  Week 12 after screening

• Number of participants with clinically significant abnormalities of Physical Examinations

  Physical Examinations include general appearance, head, ears/eyes/nose/throat, cardiovascular, respiratory, abdomen, skin, lymph nodes, extremities, musculoskeletal and neurologic and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001. Number of participants with potentially clinically significant abnormalities in physical examinations were reported as TEAEs.

  From screening up to Week 12

• Number of participants with abnormalities of Laboratory Parameters

  Laboratory Parameters include hematology, chemistry laboratory tests, urinalysis, coagulation test and plasma viral load test and will be assessed by CTCAE 5.0 to evaluate safety and tolerability of EN001. Number of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs.

  From screening up to Week 12

• Number of participants with abnormalities of 12-lead Electrocardiography (ECG)

  Categorical summarization ECG criteria were as follows: 1. QT interval, QTcB, QTcF and QTcP: increase from baseline \>30 millisecond \[ms\] or 60 ms; absolute value \> 450 ms, \>480 ms, and \> 500 ms; 2. heart rate (HR): change from baseline ≥20 beats per minute \[bpm\] and absolute value≤50 bpm or ≥120 bpm; 3. PR interval: absolute value ≥220 ms and increase from baseline≥20 ms; 4. QRS: ≥120 ms.

  From screening to baseline on Day 0 (Predose to end of infusion and 90 min after completion of infusion)

Secondary Outcomes (4)

• Incidence of adverse events (AEs)

  From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)

• Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters

  From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)

• Rate of change at the time of visit compared to baseline (percent [%]) in CK level

  From screening up to the end of support (up to approximately 5 years per subject at each visit)

• Change from baseline in Function tests

  Screening and baseline on Day -1 (up to approximately 5 years per subject after Week 12)

Study Arms (2)

Dose group A (Low dose)

EXPERIMENTAL

Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m\^2) + Chlorpheniramine (1 mg for 2\~6 years old; 2 mg for 6\~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.

Drug: EN001

Dose group B (High dose)

EXPERIMENTAL

Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m\^2) + Chlorpheniramine (1 mg for 2\~6 years old; 2 mg for 6\~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.

Drug: EN001

Interventions

EN001 DRUG

EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows. Dose group A (Low dose): 5.0x10\^5 cells/kg

Also known as: EN001 (Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells)

Dose group A (Low dose)

Eligibility Criteria

• Age: 2 Years - 18 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Those aged 2 to 18 years old
• Male
• Those who are diagnosed with DMD due to a mutation in the dystrophin gene identified by a genetic test
• Phenotypic evidence of DMD
• Clinical signs or symptoms (proximal weakness, waddling gait, Gowers maneuver)
• Elevated serum creatine kinase level
• Those who have been using systemic corticosteroids at a stable dose for 24 weeks prior to screening and are expected to maintain the constant dose throughout the study period
• Those who agree to use effective contraceptive measures until the short-term follow-up period of the clinical trial. In addition, their partner must also use a medically acceptable method of contraception (ie, oral contraceptives for women) for the same period.
• Those who are willing to agree with the ICF and whose parent or representative is willing to provide written consent for the subject's participation in the clinical trial

You may not qualify if:

• Those who have clinical signs or symptoms of cardiomyopathy, defined as LVEF \<50% on echocardiography at screening
• If ventilatory support is required during the day or if invasive mechanical ventilation via tracheostomy is used (Non-invasive ventilation such as positive pressure ventilation is allowed at night)
• If hepatitis B core antibody and hepatitis C antibody are positive
• If there is a history of major surgery within 12 weeks or it is expected during the study period
• Those who have been exposed to gene therapy or genome editing within 24 weeks from the screening
• Those who have experience with stem cell therapy
• Those who have been administered Translarna granules (Ataluren) within 24 weeks from the screening
• Those who are receiving treatment (other than corticosteroids) that may affect muscle strength or function within 12 weeks prior to screening
• If laboratory test values are abnormal at the time of screening
• Hemoglobin \<10 g/dL
• Serum albumin \<2.5 g/dL
• Platelet count \<50,000/ml
• Abnormal GGT or total bilirubin (\>laboratory's upper limit of normal)
• Abnormal renal function (Serum creatinine \>1.5 Times laboratory's upper limit of normal)"
• Those with significant neuromuscular or genetic diseases other than DMD

Sponsors & Collaborators

• ENCell: lead

Study Sites (1)

Samsung Medical Center

Seoul, South Korea

Location

MeSH Terms

Conditions

Muscular Dystrophy, Duchenne

Condition Hierarchy (Ancestors)

Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 6, 2022
• First Posted: April 20, 2022
• Study Start: January 18, 2022
• Primary Completion: December 28, 2022
• Study Completion: December 28, 2022
• Last Updated: August 30, 2024

Record last verified: 2024-08

Locations

KR (1)